BDTX
Black Diamond Therapeutics, Inc.
Key Financials
Net Income
$22.4M
↑ 132.1%
Revenue
$0
NaN%
Operating Income
$12.5M
↑ 115.9%
Total Assets
$143.0M
↑ 16.6%
Shareholders' Equity
$112.2M
↑ 34.7%
Total Liabilities
$30.8M
↓ 21.7%
EPS (Diluted)
$0.39
↑ 130.7%
Cash & Equivalents
$21.0M
↓ 42.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 7/27/2026 | View on SEC |
| SCHEDULE 13G/A | 7/8/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BDTX |
| Company Name | Black Diamond Therapeutics, Inc. |
| CIK | 1701541 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 617-417-5868 |